Amphastar Pharmaceuticals Inc vs American States Water Company — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while American States Water Company trades at $87.53 (market cap $3.43B). The key difference: American States Water Company is far larger — about 4× Amphastar Pharmaceuticals Inc's market cap, and American States Water Company pays a 2.52% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | AWR | |
|---|---|---|
Market Cap | $863.95M | $3.43B |
Sector | Health | Utilities |
52-Week High | $30.81 | $89.28 |
52-Week Low | $16.87 | $70.10 |
Enterprise Value | $1.26B | $4.33B |
Dividend Yield | — | 2.52% |
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
American States Water (AWR) trades at $87.39, up 2.01% today, with strong technical momentum showing bullish moving averages and support at $86. The company reported Q2 2026 EPS of $1.09, beating estimates by 19.1%, driven by water rate increases and 11.2% revenue growth. AWR maintains exceptional profitability with 20.52% net margins and recently announced an 8.2% dividend increase, extending its 71-year dividend growth streak.
While AWR demonstrates operational excellence and dividend reliability, the stock faces valuation concerns with a P/E of 23.65 above sector averages. Analyst sentiment is mixed with only 20% buy ratings, reflecting concerns about limited upside. Regulatory dependency and high capital expenditures present ongoing risks, though the company's monopoly position and infrastructure investments provide stability.
Trailing returns across standard periods
Latest headlines on both assets
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →American States Water provides water and electric services to over one million people in the U.S. It also manages water and wastewater systems for various military bases under long-term privatization contracts.
Read more on AWR →